HYDRUS7 LABS FORGES PARTNERSHIP WITH EPILLO HEALTH SYSTEMS

HIGHLIGHTS

  • US–based Hydrus7 Labs and Europe-based Epillo Health Systems.
  • This alliance will help Epillo to accelerate the execution of its Distributed ledger model-based Digital Therapeutic Devices.

Hydrus7 Labs from the United States of America (USA) has forged a partnership with Europe-based Epillo Health Systems. Epillo is a Digital Health company based on Blockchain. This alliance is going to help Epillo Health Systems to accelerate the execution of its Digital Therapeutic Devices (DTx) that is based on Distributed ledger model.

Epillo Health Systems, has patent-pending innovations in 153 countries through the United States Patent & Trademark Office (USPTO). In 27 countries of the European Union (EU), it has patent-pending innovations through the European Patent Office (EPO). Epillo is working to transform the Digital Healthcare technology landscape by incorporating the best of Artificial Intelligence (AI), Machine learning (ML), and Blockchain in Digital Healthcare. Hydrus 7 Labs is a Venture of JD COIN LLC. Epillo Health Systems aggressively wants to expand its innovation portfolio, along with broadening and accelerating product development in both Europe as well as USA.

Along with Mr. Jhon Banga and Dr. Deepak Parashar, Dr. Bhupinder Singh, the CEO of Hydrus7 Labs, led the agreement on behalf of Hydrus7 labs. After the partnership became official, the New board of Epillo Health Systems, chaired by Dr. Bhupinder Singh of Hydrus7 Labs, appointed Epillo’s existing founder and Director Mr. Aasif Shah as the Chief Executive Officer (CEO) of projects such as DTx which is Epillo’s user-facing and clinical use solutions. Mr. Shah will also oversee products. Backed by Intellectual Property (IP), DTx is slated to launch in MAY 2021.

Epillo’s DTx are patient-facing software applications that can help patients to treat, prevent, or manage the disease. For example, Digital Therapeutics can not only support patients in self-managing symptoms, it can also offer benefits to their current therapies and thereby enable them to improve their quality of life, along with other clinical endpoints.

, , , , , , , , , ,